Smith & Nephew Upgraded to Add at Investec (SN)
Smith & Nephew (LON:SN) was upgraded by stock analysts at Investec to an “add” rating in a report issued on Friday, Analyst RN reports.
SN has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Tuesday. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Friday, October 25th. Finally, analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Friday, October 25th. They now have a GBX 810 ($13.10) price target on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 756.89 ($12.25).
Shares of Smith & Nephew (LON:SN) traded up 0.75% on Friday, hitting GBX 804.50. The stock had a trading volume of 2,584,527 shares. Smith & Nephew has a 52 week low of GBX 636.00 and a 52 week high of GBX 813.00. The stock has a 50-day moving average of GBX 779.6 and a 200-day moving average of GBX 768.6. The company’s market cap is £7.281 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.